DMII
Drugs Made In America Acquisition II Corp.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Drugs Made In America Acquisition II Corp.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No changes.
No changes.
Annual filing, covered
10-K parsed · Apr 15 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Apr 15 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Drugs Made In America Acquisition II Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses, which we refer to throughout this prospectus as our “initial business combination.” To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. We have assembled a strong management team with a broad network of connections and corporate relationships across the pharmaceutical industry. We are confident that we will be able to use our individual experiences as well as our networks to achieve success. Together, we will formulate an all-encompassing plan for growth, one that accounts for both organic expansion and expansion via mergers and acquisitions. In the end, we will attempt to transform our target company into a widely respected industry leader by leveraging the benefits of becoming a public company, including access to finance and equity for expansion. At the same time, we will endeavor to generate excellent returns for our shareholders. Our executive offices are located in Fort Lauderdale, FL.
Drugs Made In America Acquisition II Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses, which we refer to throughout this prospectus as our “initial business combination.” To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. We have assembled a strong management team with a broad network of connections and corporate relationships across the pharmaceutical industry. We are confident that we will be able to use our individual experiences as well as our networks to achieve success. Together, we will formulate an all-encompassing plan for growth, one that accounts for both organic expansion and expansion via mergers and acquisitions. In the end, we will attempt to transform our target company into a widely respected industry leader by leveraging the benefits of becoming a public company, including access to finance and equity for expansion. At the same time, we will endeavor to generate excellent returns for our shareholders. Our executive offices are located in Fort Lauderdale, FL.
Largest filed tie
0
filed ties
—
Same SIC code · 6
Same SEC industry code: Innventure, Inc., Artius II Acquisition Inc., Armada Acquisition Corp. III and 3 more; no measured co-movers for Drugs Made In America Acquisition II Corp..
Same SIC code · 6
Same SEC industry code: Innventure, Inc., Artius II Acquisition Inc., Armada Acquisition Corp. III and 3 more; no measured co-movers for Drugs Made In America Acquisition II Corp..
—
Drugs Made In America Acquisition II Corp.
10.21
No trades yet today.
No trades yet today.
Expected move
No implied move.
Bull2
Bear1
| Manager | Value | % base | |
|---|---|---|---|
| Karpus | $28.0M | 6.13% | +7.32% |
| MMCAP International Inc. SPC | $27.2M | 5.94% | 0.00% |
| Magnetar Financial | $27.2M | 5.94% | 0.00% |
| Glazer Capital | $23.6M | 5.15% | −0.28% |
| Highbridge | $22.6M | 4.93% | +896.08% |
| Manager | Value | % base | |
|---|---|---|---|
| Karpus | $28.0M | 6.13% | +7.32% |
| MMCAP International Inc. SPC | $27.2M | 5.94% | 0.00% |
| Magnetar Financial | $27.2M | 5.94% | 0.00% |
| Glazer Capital | $23.6M | 5.15% | −0.28% |
| Highbridge | $22.6M | 4.93% | +896.08% |